08

November

2023

|

07:29 AM

Europe/Amsterdam

Bayer Group:

Summary

Group sales of 10.342 billion euros (Fx & portfolio adj. minus 0.2 percent) / EBITDA before special items: 1.685 billion euros (minus 31.3 percent) / Sales stable at Crop Science and Pharmaceuticals and up slightly at Consumer Health (Fx & portfolio adj.) / Earnings lower at all divisions, especially Crop Science / Core earnings per share at 0.38 euros (minus 66.4 percent) / Net income at minus 4.569 billion euros, impacted by impairment losses at Crop Science due to interest rates / Free cash flow at 1.626 billion euros / CEO Anderson: “We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’” / Structural options remain under review